Br J Pharmacol 179(4):557570 Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB et al (2018a) Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
This often leads to a cycle where constipation worsens during the very period when their body is already under stress from the higher dose
Curr Med Res Opin 1990;11:638-47
The good news is, youre not powerless against muscle loss
In some studies the GLP-1 arm even had numerically fewer events, which is biologically plausible because the medication lowers triglycerides and promotes weight loss, both of which reduce pancreatitis risk on their own